CLINICAL AND ENDOSCOPIC RESPONSE TO TREAT-TO-TARGET VERSUS STANDARD OF CARE IN CROHN'S DISEASE PATIENTS TREATED WITH USTEKINUMAB: WEEK 48 RESULTS OF THE STARDUST TRIAL

被引：0
|
作者：
Danese, Silvio
Vermeire, Severine
D'Haens, Geert R.
Panes, Julian
Dignass, Axel
Magro, Fernando
Nazar, Maciej
Le Bars, Manuela
Lahaye, Marjolein
Ni, Lioudmila
Lavie, Frederic
Bravata, Ivana
Sloan, Sheldon
Daperno, Marco
Lukas, Milan
Armuzzi, Alessandro
Lowenberg, Mark
Gaya, Daniel
Peyrin-Biroulet, Laurent
机构：
来源：
GASTROENTEROLOGY | 2021年 / 160卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
105
引用
收藏
页码：S25 / S25
页数：1
相关论文
共 50 条
  • [41] Oral CBD-rich Cannabis Induces Clinical but Not Endoscopic Response in Patients with Crohn's Disease, a Randomised Controlled Trial
    Naftali, Timna
    Schleider, Lihi Bar-Lev
    Almog, Shlomo
    Meiri, David
    Konikoff, Fred M.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 (11): : 1799 - 1806
  • [42] A virtual clinic enhances the quality use of anti-TNF dose intensification and rates of treatment success using a treat-to-target approach compared with standard outpatient care in Crohn's disease
    Srinivasan, A.
    van Langenberg, D. R.
    Little, R.
    Sparrow, M. P.
    De Cruz, P.
    Ward, M. G.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S467 - S467
  • [43] CROHN'S DISEASE STRICTURES RESPOND TO DRUG TREATMENT AND TREAT-TO-TARGET INTENSE COMBINATION THERAPY IS MORE EFFECTIVE THAN STANDARD ANTI-TNF THERAPY. TWO YEAR RESULTS OF THE STRIDENT RANDOMIZED CONTROLLED TRIAL.
    Schulberg, Julien D.
    Hamilton, Amy L.
    Wright, Emily K.
    Holt, Bronte A.
    Lovett, Grace C.
    Sutherland, Tom
    Ross, Alyson L.
    Vogrin, Sara
    Kamm, Michael A.
    GASTROENTEROLOGY, 2023, 164 (06) : S221 - S222
  • [44] Crohn's Disease Strictures Respond to Drug Treatment and Treat-to-Target Intense Combination Therapy is More Effective than Standard Anti-TNF Therapy. The STRIDENT Randomised Controlled Trial
    Schulberg, J.
    Wright, E.
    Holt, B.
    Sutherland, T.
    Ross, A.
    Hamilton, A.
    Vogrin, S.
    Miller, A.
    Connell, W.
    Lust, M.
    Ding, N.
    Moore, G.
    Bell, S.
    Shelton, E.
    Christensen, B.
    De Cruz, P.
    Rong, Y.
    Kamm, M.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S328 - S330
  • [45] SUPERIOR ENDOSCOPIC AND DEEP REMISSION OUTCOMES IN ADULTS WITH MODERATE TO SEVERE CROHN'S DISEASE MANAGED WITH TREAT TO TARGET APPROACH VERSUS CLINICAL SYMPTOMS: DATA FROM CALM
    Colombel, Jean Frederic
    Panaccione, Remo
    Bossuyt, Peter
    Lukas, Milan
    Baert, Filip J.
    Vanasek, Tomas
    Danalioglu, Ahmet
    Novacek, Gottfried
    Armuzzi, Alessandro
    Hebuterne, Xavier
    Travis, Simon P.
    Danese, Silvio
    Reinisch, Walter
    Sandborn, William J.
    Rutgeerts, Paul
    Hommes, Daniel
    Schreiber, Stefan
    Neimark, Ezequiel
    Huang, Bidan
    Zhou, Qian
    Petersson, Joel H.
    Wallace, Kori
    Robinson, Anne M.
    Thakkar, Roopal B.
    D'Haens, Geert R.
    GASTROENTEROLOGY, 2017, 152 (05) : S155 - S155
  • [46] Efficacy Outcomes by Symptom-Based Response Status After Induction: Week-48 Results from the GALAXI 1 Trial of Guselkumab in Crohn's Disease
    Afzali, Anita
    Panes, Julian
    Rubin, David T.
    Sands, Bruce E.
    Reinisch, Walter
    D'Haens, Geert
    Sahoo, Aparna
    Frustaci, Mary Ellen
    Yang, Zijiang
    Sandborn, William J.
    Panaccione, Remo
    Hisamatsu, Tadakazu
    Danese, Silvio
    Andrews, Jane
    Feagan, Brian G.
    Gomez, Mario
    Terry, Natalie
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S580 - S580
  • [47] Efficacy of Guselkumab in Patients With Moderately to Severely Active Crohn's Disease Not in Clinical Response at Week 12: Results From the GALAXI 1 Study
    Panaccione, Remo
    Afzali, Anita
    D'Haens, Geert R.
    Salese, Leonardo
    Terry, Natalie A.
    Sahoo, Aparna
    Frustaci, Mary Ellen
    Yang, Zijiang
    Zittan, Eran
    Danese, Silvio
    Hisamatsu, Tadakazu
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S626 - S626
  • [48] Crohn's disease strictures respond to drug treatment, and treat-to-target intense combination therapy is more effective than standard anti-tumor necrosis factor therapy: 2-year results of the STRIDENT randomized controlled trial
    Schulberg, J.
    Wright, E.
    Hamilton, A. L.
    Holt, B.
    Lovett, G.
    Sutherland, T. R.
    Ross, A.
    Vogrin, S.
    Kamm, M. A.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 193 - 194
  • [49] CROHN'S DISEASE STRICTURES RESPOND TO DRUG TREATMENT AND TREAT-TO-TARGET INTENSE COMBINATION THERAPY IS MORE EFFECTIVE THAN STANDARD ANTI-TNF THERAPY. THE STRIDENT RANDOMISED CONTROLLED TRIAL.
    Schulberg, Julien D.
    Wright, Emily K.
    Holt, Bronte A.
    Sutherland, Tom
    Ross, Alyson
    Hamilton, Amy L.
    Vogrin, Sara
    Miller, Ashley M.
    Connell, William
    Lust, Mark
    Ding, Nik S.
    Moore, Gregory T.
    Bell, Sally J.
    Shelton, Edward
    Christensen, Britt
    De Cruz, Peter
    Rong, Yuwei J.
    Kamm, Michael A.
    GASTROENTEROLOGY, 2021, 160 (06) : S92 - S93
  • [50] Comparative Effectiveness of Ustekinumab Versus Adalimumab in Induction of Clinical Response and Remission in Crohn's Disease: Experience of a Real-World Cohort at a Tertiary Care Inflammatory Bowel Disease Referral Center
    Ahmed, Zunirah
    Venkata, Krishna
    Zhang, Nan
    Malik, Talha A.
    GASTROENTEROLOGY RESEARCH, 2019, 12 (05) : 245 - 251
12345